San Carlos, United States
Glycomine Inc., founded in 2013 and headquartered in the United States, is a biotechnology pioneer developing breakthrough orphan drugs for serious, rare metabolic disorders and protein misfolding. Their unique approach involves using replacement therapies to target specific cellular compartments, addressing conditions for which no therapeutic options currently exist.
The company's flagship drug candidate, GLM101, is designed to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a condition with a critical unmet medical need. This novel substrate replacement therapy showcases their commitment to innovative solutions in the pharmaceutical field.
In its recent funding round, Glycomine secured a $35.00M Series B investment on 23 June 2021, demonstrating strong investor confidence. The round featured prestigious investors including Novo Holdings, Abingworth, RiverVest, Asahi Kasei, Chiesi Ventures, Mission BioCapital, Remiges Ventures, Sanderling Ventures, and Sanofi Ventures. This support underscores the potential of Glycomine's innovative therapies to make a substantial impact on rare disease treatment.
